Treat-to-Target and Regular Surveillance of Inflammatory Bowel Disease Are Associated with Low Incidence and Early-Stage Detection of Malignancies: A Retrospective Cohort Study
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Follow-Up
2.2. Methods
3. Results
3.1. Study Population
3.2. Malignancies
3.3. Types of Malignancies
3.4. Mortality
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Correction Statement
References
- Torres, J.; Mehandru, S.; Colombel, J.F.; Peyrin-Biroulet, L. Crohn’s Disease. Lancet 2017, 389, 1741–1755. [Google Scholar] [CrossRef] [PubMed]
- Ungaro, R.; Mehandru, S.; Allen, P.B.; Peyrin-Biroulet, L.; Colombel, J.F. Ulcerative Colitis. Lancet 2017, 389, 1756–1770. [Google Scholar] [CrossRef]
- Wijnands, A.M.; de Jong, M.E.; Lutgens, M.W.M.D.; Hoentjen, F.; Elias, S.G.; Oldenburg, B. Dutch Initiative on Crohn and Colitis (ICC) Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Gastroenterology 2021, 160, 1584–1598. [Google Scholar] [CrossRef]
- Ekbom, A.; Helmick, C.; Zack, M.; Adami, H.O. Ulcerative Colitis and Colorectal Cancer. A Population-Based Study. N. Engl. J. Med. 1990, 323, 1228–1233. [Google Scholar] [CrossRef] [PubMed]
- Yaeger, R.; Shah, M.A.; Miller, V.A.; Kelsen, J.R.; Wang, K.; Heins, Z.J.; Ross, J.S.; He, Y.; Sanford, E.; Yantiss, R.K.; et al. Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct from Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. Gastroenterology 2016, 151, 278–287.e6. [Google Scholar] [CrossRef]
- Weismüller, T.J.; Trivedi, P.J.; Bergquist, A.; Imam, M.; Lenzen, H.; Ponsioen, C.Y.; Holm, K.; Gotthardt, D.; Färkkilä, M.A.; Marschall, H.-U.; et al. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate with Course of Primary Sclerosing Cholangitis. Gastroenterology 2017, 152, 1975–1984.e8. [Google Scholar] [CrossRef] [PubMed]
- Gordon, H.; Biancone, L.; Fiorino, G.; Katsanos, K.H.; Kopylov, U.; Sulais, E.A.; Axelrad, J.E.; Balendran, K.; Burisch, J.; de Ridder, L.; et al. ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. J. Crohn’s Colitis 2022, 17, jjac187. [Google Scholar] [CrossRef] [PubMed]
- Trivedi, P.J.; Crothers, H.; Mytton, J.; Bosch, S.; Iqbal, T.; Ferguson, J.; Hirschfield, G.M. Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People with Inflammatory Bowel Disease, Based on Sex, Race, and Age. Gastroenterology 2020, 159, 915–928. [Google Scholar] [CrossRef]
- Laukoetter, M.G.; Mennigen, R.; Hannig, C.M.; Osada, N.; Rijcken, E.; Vowinkel, T.; Krieglstein, C.F.; Senninger, N.; Anthoni, C.; Bruewer, M. Intestinal Cancer Risk in Crohn’s Disease: A Meta-Analysis. J. Gastrointest. Surg. 2011, 15, 576–583. [Google Scholar] [CrossRef]
- Axelrad, J.E.; Olén, O.; Sachs, M.C.; Erichsen, R.; Pedersen, L.; Halfvarson, J.; Askling, J.; Ekbom, A.; Sørensen, H.T.; Ludvigsson, J.F. Inflammatory Bowel Disease and Risk of Small Bowel Cancer: A Binational Population-Based Cohort Study from Denmark and Sweden. Gut 2021, 70, 297–308. [Google Scholar] [CrossRef]
- Bojesen, R.D.; Riis, L.B.; Høgdall, E.; Nielsen, O.H.; Jess, T. Inflammatory Bowel Disease and Small Bowel Cancer Risk, Clinical Characteristics, and Histopathology: A Population-Based Study. Clin. Gastroenterol. Hepatol. 2017, 15, 1900–1907.e2. [Google Scholar] [CrossRef] [PubMed]
- Lo, B.; Zhao, M.; Vind, I.; Burisch, J. The Risk of Extraintestinal Cancer in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies. Clin. Gastroenterol. Hepatol. 2021, 19, 1117–1138.e19. [Google Scholar] [CrossRef] [PubMed]
- Rungoe, C.; Simonsen, J.; Riis, L.; Frisch, M.; Langholz, E.; Jess, T. Inflammatory Bowel Disease and Cervical Neoplasia: A Population-Based Nationwide Cohort Study. Clin. Gastroenterol. Hepatol. 2015, 13, 693–700.e1. [Google Scholar] [CrossRef] [PubMed]
- Hutfless, S.; Fireman, B.; Kane, S.; Herrinton, L.J. Screening Differences and Risk of Cervical Cancer in Inflammatory Bowel Disease. Aliment. Pharmacol. Ther. 2008, 28, 598–605. [Google Scholar] [CrossRef] [PubMed]
- Mason, M.; Siegel, C.A. Do Inflammatory Bowel Disease Therapies Cause Cancer? Inflamm. Bowel Dis. 2013, 19, 1306–1321. [Google Scholar] [CrossRef] [PubMed]
- Mantovani, A.; Allavena, P.; Sica, A.; Balkwill, F. Cancer-Related Inflammation. Nature 2008, 454, 436–444. [Google Scholar] [CrossRef] [PubMed]
- Nøst, T.H.; Alcala, K.; Urbarova, I.; Byrne, K.S.; Guida, F.; Sandanger, T.M.; Johansson, M. Systemic Inflammation Markers and Cancer Incidence in the UK Biobank. Eur. J. Epidemiol. 2021, 36, 841–848. [Google Scholar] [CrossRef]
- Bye, W.A.; Ma, C.; Nguyen, T.M.; Parker, C.E.; Jairath, V.; East, J.E. Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis. Am. J. Gastroenterol. 2018, 113, 1801–1809. [Google Scholar] [CrossRef]
- Adamina, M.; Bonovas, S.; Raine, T.; Spinelli, A.; Warusavitarne, J.; Armuzzi, A.; Bachmann, O.; Bager, P.; Biancone, L.; Bokemeyer, B.; et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment. J. Crohn’s Colitis 2020, 14, 155–168. [Google Scholar] [CrossRef]
- Raine, T.; Bonovas, S.; Burisch, J.; Kucharzik, T.; Adamina, M.; Annese, V.; Bachmann, O.; Bettenworth, D.; Chaparro-Sanchez, M.; Czuber-Dochan, W.; et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J. Crohn’s Colitis 2021, 16, jjab178. [Google Scholar] [CrossRef]
- Turner, D.; Ricciuto, A.; Lewis, A.; D’Amico, F.; Dhaliwal, J.; Griffiths, A.M.; Bettenworth, D.; Sandborn, W.J.; Sands, B.E.; Reinisch, W.; et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target Strategies in IBD. Gastroenterology 2021, 160, 1570–1583. [Google Scholar] [CrossRef] [PubMed]
- Shah, S.C.; Itzkowitz, S.H. Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. Gastroenterology 2022, 162, 715–730.e3. [Google Scholar] [CrossRef] [PubMed]
- Coelho-Prabhu, N.; Lewis, J.D. Update on Endoscopic Dysplasia Surveillance in Inflammatory Bowel Disease. Am. J. Gastroenterol. 2023, 118, 1748–1755. [Google Scholar] [CrossRef] [PubMed]
- Murthy, S.K.; Feuerstein, J.D.; Nguyen, G.C.; Velayos, F.S. AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. Gastroenterology 2021, 161, 1043–1051.e4. [Google Scholar] [CrossRef] [PubMed]
- Gupta, R.B.; Harpaz, N.; Itzkowitz, S.; Hossain, S.; Matula, S.; Kornbluth, A.; Bodian, C.; Ullman, T. Histologic Inflammation Is a Risk Factor for Progression to Colorectal Neoplasia in Ulcerative Colitis: A Cohort Study. Gastroenterology 2007, 133, 1099–1105. [Google Scholar] [CrossRef] [PubMed]
- Olén, O.; Erichsen, R.; Sachs, M.C.; Pedersen, L.; Halfvarson, J.; Askling, J.; Ekbom, A.; Sørensen, H.T.; Ludvigsson, J.F. Colorectal Cancer in Ulcerative Colitis: A Scandinavian Population-Based Cohort Study. Lancet 2020, 395, 123–131. [Google Scholar] [CrossRef]
- Olén, O.; Erichsen, R.; Sachs, M.C.; Pedersen, L.; Halfvarson, J.; Askling, J.; Ekbom, A.; Sørensen, H.T.; Ludvigsson, J.F. Colorectal Cancer in Crohn’s Disease: A Scandinavian Population-Based Cohort Study. Lancet Gastroenterol. Hepatol. 2020, 5, 475–484. [Google Scholar] [CrossRef]
- Lutgens, M.W.M.D.; van Oijen, M.G.H.; van der Heijden, G.J.M.G.; Vleggaar, F.P.; Siersema, P.D.; Oldenburg, B. Declining Risk of Colorectal Cancer in Inflammatory Bowel Disease: An Updated Meta-Analysis of Population-Based Cohort Studies. Inflamm. Bowel. Dis. 2013, 19, 789–799. [Google Scholar] [CrossRef]
- Castaño-Milla, C.; Chaparro, M.; Gisbert, J.P. Systematic Review with Meta-Analysis: The Declining Risk of Colorectal Cancer in Ulcerative Colitis. Aliment. Pharmacol. Ther. 2014, 39, 645–659. [Google Scholar] [CrossRef]
- Jess, T.; Loftus, E.V.; Velayos, F.S.; Harmsen, W.S.; Zinsmeister, A.R.; Smyrk, T.C.; Schleck, C.D.; Tremaine, W.J.; Melton, L.J.; Munkholm, P.; et al. Risk of Intestinal Cancer in Inflammatory Bowel Disease: A Population-Based Study from Olmsted County, Minnesota. Gastroenterology 2006, 130, 1039–1046. [Google Scholar] [CrossRef]
- Jess, T.; Simonsen, J.; Jørgensen, K.T.; Pedersen, B.V.; Nielsen, N.M.; Frisch, M. Decreasing Risk of Colorectal Cancer in Patients with Inflammatory Bowel Disease over 30 Years. Gastroenterology 2012, 143, 375–381.e1. [Google Scholar] [CrossRef] [PubMed]
- Bosetti, C.; Traini, E.; Alam, T.; Allen, C.A.; Carreras, G.; Compton, K.; Fitzmaurice, C.; Force, L.M.; Gallus, S.; Gorini, G.; et al. National Burden of Cancer in Italy, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Sci. Rep. 2020, 10, 22099. [Google Scholar] [CrossRef] [PubMed]
- Choi, C.-H.R.; Rutter, M.D.; Askari, A.; Lee, G.H.; Warusavitarne, J.; Moorghen, M.; Thomas-Gibson, S.; Saunders, B.P.; Graham, T.A.; Hart, A.L. Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview. Am. J. Gastroenterol. 2015, 110, 1022–1034. [Google Scholar] [CrossRef] [PubMed]
- Yano, Y.; Matsui, T.; Hirai, F.; Okado, Y.; Sato, Y.; Tsurumi, K.; Ishikawa, S.; Beppu, T.; Koga, A.; Yoshizawa, N.; et al. Cancer Risk in Japanese Crohn’s Disease Patients: Investigation of the Standardized Incidence Ratio. J. Gastroenterol. Hepatol. 2013, 28, 1300–1305. [Google Scholar] [CrossRef] [PubMed]
- Seishima, R.; Okabayashi, K.; Ikeuchi, H.; Uchino, M.; Futami, K.; Noguchi, T.; Ohge, H.; Iseki, Y.; Watanabe, K.; Itabashi, M.; et al. Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study. Am. J. Gastroenterol. 2023, 118, 1248–1255. [Google Scholar] [CrossRef] [PubMed]
- Kabir, M.; Thomas-Gibson, S.; Ahmad, A.; Kader, R.; Al-Hillawi, L.; Mcguire, J.; David, L.; Shah, K.; Rao, R.; Vega, R.; et al. Cancer Biology or Ineffective Surveillance? A Multicentre Retrospective Analysis of Colitis-Associated Post-Colonoscopy Colorectal Cancers. J. Crohn’s Colitis 2023, jjad189. [Google Scholar] [CrossRef] [PubMed]
- Piovani, D.; Hassan, C.; Repici, A.; Rimassa, L.; Carlo-Stella, C.; Nikolopoulos, G.K.; Riboli, E.; Bonovas, S. Risk of Cancer in Inflammatory Bowel Diseases: Umbrella Review and Reanalysis of Meta-Analyses. Gastroenterology 2022, 163, 671–684. [Google Scholar] [CrossRef] [PubMed]
- Nyboe Andersen, N.; Pasternak, B.; Basit, S.; Andersson, M.; Svanström, H.; Caspersen, S.; Munkholm, P.; Hviid, A.; Jess, T. Association between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients with Inflammatory Bowel Disease. JAMA 2014, 311, 2406–2413. [Google Scholar] [CrossRef]
- Lichtenstein, G.R.; Rutgeerts, P.; Sandborn, W.J.; Sands, B.E.; Diamond, R.H.; Blank, M.; Montello, J.; Tang, L.; Cornillie, F.; Colombel, J.-F. A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients with Inflammatory Bowel Disease. Am. J. Gastroenterol. 2012, 107, 1051–1063. [Google Scholar] [CrossRef]
- Williams, C.J.M.; Peyrin-Biroulet, L.; Ford, A.C. Systematic Review with Meta-Analysis: Malignancies with Anti-Tumour Necrosis Factor-α Therapy in Inflammatory Bowel Disease. Aliment. Pharmacol. Ther. 2014, 39, 447–458. [Google Scholar] [CrossRef]
- Holmer, A.K.; Luo, J.; Russ, K.B.; Park, S.; Yang, J.Y.; Ertem, F.; Dueker, J.; Nguyen, V.; Hong, S.; Zenger, C.; et al. Comparative Safety of Biologic Agents in Patients with Inflammatory Bowel Disease with Active or Recent Malignancy: A Multi-Center Cohort Study. Clin. Gastroenterol. Hepatol. 2023, 21, 1598–1606.e5. [Google Scholar] [CrossRef] [PubMed]
- D’Amico, F.; Parigi, T.L.; Bonovas, S.; Peyrin-Biroulet, L.; Danese, S. Long-Term Safety of Approved Biologics for Ulcerative Colitis. Expert Opin. Drug Saf. 2020, 19, 807–816. [Google Scholar] [CrossRef] [PubMed]
- Peyrin-Biroulet, L.; Rahier, J.-F.; Kirchgesner, J.; Abitbol, V.; Shaji, S.; Armuzzi, A.; Karmiris, K.; Gisbert, J.P.; Bossuyt, P.; Helwig, U.; et al. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease. Clin. Gastroenterol. Hepatol. 2023, 21, 771–788.e10. [Google Scholar] [CrossRef] [PubMed]
- Beaugerie, L.; Brousse, N.; Bouvier, A.M.; Colombel, J.F.; Lémann, M.; Cosnes, J.; Hébuterne, X.; Cortot, A.; Bouhnik, Y.; Gendre, J.P.; et al. Lymphoproliferative Disorders in Patients Receiving Thiopurines for Inflammatory Bowel Disease: A Prospective Observational Cohort Study. Lancet 2009, 374, 1617–1625. [Google Scholar] [CrossRef] [PubMed]
- Sokol, H.; Beaugerie, L.; Maynadié, M.; Laharie, D.; Dupas, J.-L.; Flourié, B.; Lerebours, E.; Peyrin-Biroulet, L.; Allez, M.; Simon, T.; et al. Excess Primary Intestinal Lymphoproliferative Disorders in Patients with Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2012, 18, 2063–2071. [Google Scholar] [CrossRef]
- Khan, N.; Abbas, A.M.; Lichtenstein, G.R.; Loftus, E.V.; Bazzano, L.A. Risk of Lymphoma in Patients with Ulcerative Colitis Treated with Thiopurines: A Nationwide Retrospective Cohort Study. Gastroenterology 2013, 145, 1007–1015.e3. [Google Scholar] [CrossRef]
- Te Groen, M.; Derks, M.; den Broeder, N.; Peters, C.; Dijkstra, G.; de Vries, A.; Romkens, T.; Horjus, C.; de Boer, N.; de Jong, M.; et al. Quality of Surveillance Impacts the Colitis-Associated Advanced Neoplasia Risk: A Multicenter Case-Control Study. Clin. Gastroenterol. Hepatol. 2022. [Google Scholar] [CrossRef]
- Stjärngrim, J.; Ekbom, A.; Hammar, U.; Hultcrantz, R.; Forsberg, A.M. Rates and Characteristics of Postcolonoscopy Colorectal Cancer in the Swedish IBD Population: What Are the Differences from a Non-IBD Population? Gut 2019, 68, 1588–1596. [Google Scholar] [CrossRef]
Patient Characteristics | Number |
---|---|
Total population | 5239 |
Total person-years | 19,820 |
Female | 2515 (48%) |
IBD type | |
UC | 3083 (58.9%) |
CD | 2142 (40.9%) |
IBD-U | 13 (0.2%) |
Age mean (SD) | 40.4 (15.0) |
Characteristics of IBD Patients Who Developed Cancer | |
---|---|
Number (%) (Range) | |
Age at cancer diagnosis | 52.9 (19–78) |
Sex | Male 39 (55.7) |
Female 31 (44.3) | |
IBD type | UC 32 (45.7) |
CD 38 (54.3) | |
Drug exposure | Aminosalicylates 62% |
Antimetabolite 40% | |
Biologics 43% | |
Family * history of cancer | 31% |
Smoker (past or current) | 64% |
Cancer Incidence | |||
---|---|---|---|
Malignancies | Incidence Rate per 100,000 Patient Years | Standardized Incidence Rate (SIR) | |
All cancers | 71 | 358 (95% CI 275–444) | 0.93 (95% CI 0.73–1.16) |
CRC | 9 | 45 (95% CI 15–74) | 1.18 (95% CI 0.54–2.09) |
CRC in UC | 6 | 57 (95% CI 21–124) | 1.49 (95% CI 1.00–1.98) |
Total | UC | CD | |
---|---|---|---|
Gastrointestinal | 17 (24%) | 8 | 9 |
Stomach | 2 | ||
Small bowel | 5 | ||
Colon and rectum | 6 | 3 | |
Anus | 1 | ||
Melanoma | 8 (11.2%) | 4 | 4 |
Breast | 8 (11.2%) | 4 | 4 |
Prostate | 7 (9.9%) | 5 | 2 |
Bladder | 6 (8.4%) | 3 | 3 |
Thyroid | 5 (7.0%) | 2 | 3 |
Hematologic | 4 (5.6%) | 4 | |
Lung | 4 (5.6%) | 2 | 2 |
Testicle | 3 (4.2%) | 2 | 1 |
Ovary | 2 (2.8%) | 1 | 1 |
Kidney | 2 (2.8%) | 1 | 1 |
Head–nose–throat | 2 (2.8%) | 1 | 1 |
Pancreas | 1 (1.4%) | 1 | |
Non-melanoma skin cancer | 1 (1.4%) | 1 |
Early (I–II) Stage | Advanced Stage (III–IV) | |
---|---|---|
Small bowel | 4 | 1 |
Colon and rectum | 7 | 2 |
Anus | 0 | 1 |
Melanoma | 4 | 0 |
Non-melanoma skin cancer | 1 | 0 |
Hematologic | 4 | 0 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Parigi, T.L.; Allocca, M.; Furfaro, F.; D’Amico, F.; Zilli, A.; Dal Buono, A.; Gabbiadini, R.; Bonovas, S.; Armuzzi, A.; Danese, S.; et al. Treat-to-Target and Regular Surveillance of Inflammatory Bowel Disease Are Associated with Low Incidence and Early-Stage Detection of Malignancies: A Retrospective Cohort Study. Cancers 2023, 15, 5754. https://doi.org/10.3390/cancers15245754
Parigi TL, Allocca M, Furfaro F, D’Amico F, Zilli A, Dal Buono A, Gabbiadini R, Bonovas S, Armuzzi A, Danese S, et al. Treat-to-Target and Regular Surveillance of Inflammatory Bowel Disease Are Associated with Low Incidence and Early-Stage Detection of Malignancies: A Retrospective Cohort Study. Cancers. 2023; 15(24):5754. https://doi.org/10.3390/cancers15245754
Chicago/Turabian StyleParigi, Tommaso Lorenzo, Mariangela Allocca, Federica Furfaro, Ferdinando D’Amico, Alessandra Zilli, Arianna Dal Buono, Roberto Gabbiadini, Stefanos Bonovas, Alessandro Armuzzi, Silvio Danese, and et al. 2023. "Treat-to-Target and Regular Surveillance of Inflammatory Bowel Disease Are Associated with Low Incidence and Early-Stage Detection of Malignancies: A Retrospective Cohort Study" Cancers 15, no. 24: 5754. https://doi.org/10.3390/cancers15245754
APA StyleParigi, T. L., Allocca, M., Furfaro, F., D’Amico, F., Zilli, A., Dal Buono, A., Gabbiadini, R., Bonovas, S., Armuzzi, A., Danese, S., & Fiorino, G. (2023). Treat-to-Target and Regular Surveillance of Inflammatory Bowel Disease Are Associated with Low Incidence and Early-Stage Detection of Malignancies: A Retrospective Cohort Study. Cancers, 15(24), 5754. https://doi.org/10.3390/cancers15245754